Genomenon

By A2Hub Editorial. Published 2026-04-22. Last updated: 2026-04-22.

At a glance

• Founded: Mid-2010s, as a U-M spinout
• Founders: Mark Kiel (chief science officer) and a U-M-affiliated founding team
• HQ: Ann Arbor, Michigan
• Funding raised: Approximately $36.8M total, including a $20M Series B led by Beringea in 2022
• Customers: 1,000+ genetic testing labs, hospitals, pharmaceutical companies, and research institutions
• Flagship product: Mastermind Genomic Search Engine, indexing 40M+ scientific articles for genetic variant evidence
• Status: Private, growth-stage
• Website: genomenon.com

The pitch in one line

Genomenon is the company that turned the entire searchable corpus of human genetics literature into a workflow tool. The Mastermind search engine indexes more than 40 million scientific articles for variant-level evidence, and 1,000+ genetic testing labs and hospitals use it to interpret patient results in real clinical workflows.

Founding story: a clinical pathologist solves a search problem

Genomenon was founded by Mark Kiel, a clinical molecular pathologist trained at the University of Michigan, alongside collaborators from the U-M genomics community. The thesis was specific. Clinical genetic testing had become widely available by the mid-2010s, but the bottleneck in the workflow had moved. The lab could sequence a patient's genome quickly. The hard part was interpreting which of the many variants the sequence contained were clinically meaningful.

The evidence for clinical meaning lives in the scientific literature. Tens of thousands of papers describe specific variants and their clinical implications. A clinical lab interpreting a patient result needed to find every mention of every relevant variant in that literature, which was a search problem that consumer search engines (Google, PubMed) were not built to solve. The traditional workflow was a human expert manually searching, reading, and synthesizing literature for each report, which capped the throughput of clinical interpretation regardless of how fast the sequencing got.

Genomenon's bet was that a purpose-built search engine, indexing the full text of scientific literature with variant-level granularity, would change the economics of clinical interpretation. Mastermind, the product that came out of that bet, became the workflow tool of choice for clinical labs trying to scale interpretation against growing volumes of sequencing data.

What they build

Genomenon's flagship product is the Mastermind Genomic Search Engine. The platform indexes more than 40 million scientific articles, full-text where available, with variant-level structured metadata that lets a clinical lab pose questions like "give me every published paper that mentions BRCA1 variant X" and get a curated answer in seconds rather than hours.

Adjacent products and services span:

Mastermind Pro. The clinical workflow tool used by genetic testing labs and hospital genomics programs.

Mastermind for pharma. Curated evidence services and platform access for pharmaceutical and biotech customers conducting variant landscape analysis, biomarker development, and clinical trial enrollment work.

Curated genomic landscapes. Bespoke evidence reports built by Genomenon's scientific team for pharma customers across rare disease, oncology, and other variant-driven therapeutic areas.

API and integration. Programmatic access to the index for customers integrating Mastermind into their own clinical or research workflows.

The customer base spans more than 1,000 genetic testing labs, hospitals, pharmaceutical companies, and research institutions globally. The customer profile is split between clinical-workflow users (labs and hospitals) and life-sciences research users (pharma and biotech).

Funding history

Genomenon has raised approximately $36.8M in total disclosed funding across institutional rounds. The most prominent round was a $20M Series B led by Beringea in 2022, with additional participation from existing investors. Beringea is a UK and US-based growth-stage fund with a meaningful Ann Arbor presence; the firm has also been an investor in ArborMetrix and other Ann Arbor healthcare data companies.

The capital strategy has been deliberate. Genomenon has raised enough to scale customer growth and product development without pursuing the kind of breakneck growth-equity round that would force a sale or a public listing. The pharma services arm provides a profitable revenue stream that complements the recurring software revenue from the clinical lab customer base.

Ann Arbor footprint

Genomenon is headquartered in Ann Arbor and operates a team that combines scientific staff (clinical and molecular geneticists), software engineers (search infrastructure, NLP, web), and customer-facing staff. The headcount is meaningful but not large; the company operates in the dozens-to-low-hundreds range typical of focused B2B SaaS firms in Ann Arbor.

The U-M connection is direct. The founding team's training, the recruiting pipeline for scientific staff, and the broader Ann Arbor genomics community are all part of Genomenon's operating environment. The company has been a recurring presence at U-M genomics and bioinformatics events.

Leadership and people

Mark Kiel has been the chief science officer and a founding leadership figure throughout the company's history. The CEO role has rotated through a small set of operators with backgrounds across healthcare IT and life sciences software. Current operating leadership and the day-to-day status of founder roles should be cross-checked on the company website before citing in detail.

Why it matters

Three reasons Genomenon matters in the Ann Arbor story.

First, it is the cleanest example of an Ann Arbor AI company applied to a problem with serious public health stakes. Clinical interpretation of genetic variants directly affects patient care, particularly in rare disease, hereditary cancer, and pharmacogenomics. Genomenon's product is in the workflow when those clinical decisions get made.

Second, it sits inside the Ann Arbor health data and analytics cluster: ArborMetrix, Strata Oncology, Truven Health Analytics (now Merative), and Genomenon all share data scientists, software engineers, and customer overlap across pharma and provider networks. That cluster effect is part of how Ann Arbor maintains health-data depth against coastal competition.

Third, the search-engine-for-genomics positioning is strategically defensible. Search infrastructure is hard to displace once it becomes embedded in a clinical workflow. Each year that Mastermind is the default search tool for thousands of labs, the switching costs grow. That is the kind of moat that compounds over a decade.

Related

• BlueConduit is the other prominent Ann Arbor AI company applied to a public-interest problem.
• Strata Oncology is the Ann Arbor precision oncology network with overlapping pharma customers.
• ArborMetrix is the Ann Arbor real-world healthcare data company that shares investor and customer overlap.
• The AI category hub covers the full Ann Arbor AI bench.
• The companies directory is the master index.

FAQ

Where is Genomenon headquartered? Genomenon is headquartered in Ann Arbor, Michigan.

What does Genomenon do? Genomenon builds the Mastermind Genomic Search Engine, a search platform that indexes more than 40 million scientific articles with variant-level structured metadata. The product is used by clinical genetic testing labs, hospitals, pharmaceutical companies, and research institutions to interpret variant evidence in clinical and research workflows.

Who founded Genomenon? Mark Kiel, a clinical molecular pathologist trained at the University of Michigan, founded Genomenon with collaborators from the U-M genomics community.

How much funding has Genomenon raised? Approximately $36.8M in total funding, including a $20M Series B led by Beringea in 2022.

Who are Genomenon's customers? The customer base spans more than 1,000 genetic testing labs, hospitals, pharmaceutical companies, and research institutions globally. Use cases span clinical interpretation, pharmaceutical biomarker development, and rare-disease landscape analysis.

How does Mastermind differ from PubMed or Google Scholar? PubMed and Google Scholar are general-purpose academic search tools. Mastermind is a domain-specific search engine indexed for genetic variants, with variant-level structured metadata and clinical-workflow integration that consumer search engines do not provide. The result is that a clinical lab can find variant-specific evidence in seconds rather than the hours required for manual literature search.

Is Genomenon hiring in Ann Arbor? Yes. Open roles in software engineering (search infrastructure and NLP), bioinformatics, scientific curation, product, and commercial functions are posted at genomenon.com/careers. The work model is hybrid with Ann Arbor as the home base and remote flexibility for specific roles.

Is Genomenon profitable? Genomenon has been deliberate about capital efficiency and diversification of revenue. The company does not publish financial statements, but the combination of recurring software revenue from the clinical lab customer base and pharma services revenue has given it room to scale without pursuing growth-equity rounds that would force a near-term exit.

Strategic reading

Genomenon competes in a category that has only existed for about a decade. Precision medicine and clinical genetic testing have created a sustained demand for variant-level evidence interpretation, and the underlying data problem (the unstructured, sprawling, accelerating scientific literature on human genetics) is not getting easier for humans to navigate. Competitors include purpose-built clinical variant databases (ClinVar is the free reference, with commercial overlays from several vendors), curated knowledge bases built by individual labs and consortia, and broader AI-literature search tools that are not specialized for genomics. Genomenon's differentiation is the combination of full-text literature coverage, variant-level structured metadata, and the depth of clinical and pharma workflows built on top of the search index.

The bull case: Mastermind's embedded position inside 1,000-plus labs and hospitals is genuinely hard to displace, the pharma services business expands the revenue mix beyond software subscriptions, and the generative-AI wave that arrived in 2023 has made curated, domain-specific search indexes more valuable (not less), because LLM-based clinical tools need trustworthy retrieval over a controlled corpus rather than a scraped open-web model.

The bear case: competing variant-interpretation tools are improving, some large clinical lab customers could build or acquire the capability in-house, and the regulatory environment for clinical decision support is tightening. Genomenon will need to continue investing in clinical evidence, workflow integrations, and scientific curation to stay ahead of those pressures. So far the company has done that methodically.